Immuneering Corporation (IMRX) vs Atrium Therapeutics, Inc. (RNA)
A side-by-side comparison of Immuneering Corporation and Atrium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMRX
Immuneering Corporation
$3.87HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT
RNA
Atrium Therapeutics, Inc.
$8.03HealthcareDelayed quote: Oct 6, 2026, 2:05 PM EDT
Total return — IMRX vs RNA
growth of $100 · dividends reinvested · last 1yIMRX -19.0% (-19.0%/yr)RNA -46.0% (-46.0%/yr)IMRX compounded faster over this window
IMRX RNA
IMRX vs RNA: by the numbers
- •IMRX is the larger company ($140M vs $137M market cap).
- •Both run net losses; IMRX's is the smaller (0.00% vs -396.52% net margin).
Metrics side by side
Valuation
| Metric | IMRX | RNA |
|---|---|---|
| P/S ratio | N/A | 5.85 |
| P/B ratio | 0.74 | 0.64 |
Profitability
| Metric | IMRX | RNA |
|---|---|---|
| Gross margin | 0.00% | 97.90% |
| Operating margin | 0.00% | -410.23% |
| Net margin | 0.00% | -396.52% |
| ROE | -30.03% | -43.42% |
| ROIC | -32.73% | -38.45% |
Growth (annualized)
| Metric | IMRX | RNA |
|---|---|---|
| Total return CAGR (5Y) | -32.77% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.